FIELD: medicine, pharmaceutics.
SUBSTANCE: group of inventions relates to methods of detecting and measurement of presence or level of anti-TNFα medications and autoantibodies in samples and includes comparison of quantity of labelled complex and quantity of free labelled TNFα or anti-TNFα medication with standard curve.
EFFECT: group of inventions are applied for optimisation of treatment and monitoring of patients, obtaining anti-TNFα medications, for detection of presence or level of autoantibodies (for instance, HACA and/or HAHA) against preparation.
20 cl, 25 dwg, 5 tbl, 12 ex
